221 related articles for article (PubMed ID: 17293140)
1. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
Cao H; Zhang H; Zheng X; Gao D
J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
3. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
Zeng H; Zhang H
J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
5. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds.
Srivani P; Sastry GN
J Mol Graph Model; 2009 Feb; 27(6):676-88. PubMed ID: 19147382
[TBL] [Abstract][Full Text] [Related]
6. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
7. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
8. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Moskey MD; Pease LJ; Stewart KD; Yates M; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2006 Aug; 16(16):4326-30. PubMed ID: 16735117
[TBL] [Abstract][Full Text] [Related]
9. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
Awale M; Mohan CG
J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
[TBL] [Abstract][Full Text] [Related]
13. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity.
Salum LB; Polikarpov I; Andricopulo AD
J Chem Inf Model; 2008 Nov; 48(11):2243-53. PubMed ID: 18937440
[TBL] [Abstract][Full Text] [Related]
14. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors.
Tintori C; Magnani M; Schenone S; Botta M
Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
16. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
San Juan AA
Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
[TBL] [Abstract][Full Text] [Related]
17. Molecular modelling studies on d-annulated benzazepinones as VEGF-R2 kinase inhibitors using docking and 3D-QSAR.
Lan P; Sun JR; Chen WN; Sun PH; Chen WM
J Enzyme Inhib Med Chem; 2011 Jun; 26(3):367-77. PubMed ID: 20846090
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
Caballero J; Fernández M; González-Nilo FD
Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
[TBL] [Abstract][Full Text] [Related]
19. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
[TBL] [Abstract][Full Text] [Related]
20. Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein.
San Juan AA
J Mol Graph Model; 2007 Sep; 26(2):482-93. PubMed ID: 17446106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
